| Section | Status | BlueTeq | Name |
| 08.03.04.02 | Formulary |  |
Abiraterone Zytiga® |
| 08.01.05 | Formulary | |
Alectinib Alecensa® |
| 08.02.03 | Formulary | |
Alemtuzumab Lemtrada® |
| 08.01.05 | Formulary | |
Arsenic Trioxide Trisenox® |
| 08.02.04 | Formulary | |
Atezolizumab (Tecentriq®) |
| 08.02.04 | Formulary | |
Avelumab (Bavencio®) |
| 08.02.04 | Formulary | |
Axicabtagene ciloleuce (Yescarta®) |
| 08.01.01 | Formulary | |
Bendamustine |
| 08.01.05 | Formulary | |
Bevacizumab Avastin® |
| 08.02 | Formulary | |
Blinatumomab Blincyto® |
| 08.01.05 | Formulary | |
Bortezomib Velcade® |
| 08.01.05 | Formulary | |
Bosutinib Bosulif® |
| 08.01.05 | Formulary | |
Cabazitaxel Jevtana® |
| 08.01.05 | Formulary | |
Carfilzomib Kyprolis® |
| 08.01.05 | Formulary | |
Ceritinib Zykadia |
| 08.01.05 | Formulary | |
Cetuximab Erbitux® |
| 08.01.03 | Formulary | |
Clofarabine Evoltra® |
| 08.01.05 | Formulary | |
Crizotinib Xalkori® |
| 08.01.05 | Formulary | |
Dacomitinib Vizimpro®) |
| 08.02.04 | Formulary | |
Daratumumab (Darzalex®) |
| 08.01.05 | Restricted Use | |
Dasatinib Sprycel® |
| 08.02.04 | Formulary | |
Dinutuximab (Qarziba®) |
| 08.01.02 | Formulary | |
Doxorubicin Caelyx® |
| 08.02.04 | Formulary | |
Durvalumab (Imfinzi® ) |
| 08.01.05 | Formulary | |
Eribulin Halaven® |
| 08.01.05 | Restricted Use | |
Everolimus Afinitor® |
| 08.02.04 | Formulary | |
Glatiramer Acetate Copaxone® |
| 05.03.03.02 | Formulary | |
Glecaprevir and Pibrentasvir Maviret® |
| 08.02.04 | Formulary | |
Immunocellular therapy containing tisagenlecleucel, autologous T cells genetically modified ex vivo using a lentiviral vector encoding an anti-CD19 chimeric antigen receptor (CAR) (Kymriah®) |
| 08.01 | Formulary | |
Inotuzumab ozogamicin Besponsa® |
| 08.02.04 | Formulary | |
Interferon Beta Avonex® |
| 08.02.04 | Formulary | |
Interferon Beta Rebif® |
| 08.02.04 | Formulary | |
Interferon Beta Betaferon® |
| 08.01.05 | Formulary | |
Ipilimumab Yervoy® |
| 08.01.05 | Formulary | |
Larotrectinib |
| 08.02.04 | Formulary | |
Lenalidomide |
| 08.01.05 | Formulary | |
Lenvatinib Lenvima® and Kisplyx® |
| 08.01.05 | Formulary | |
Lorlatinib |
| 08.01.05 | Formulary | |
Midostaurin Rydapt® |
| 08.02.04 | Formulary | |
Natalizumab Tysabri® |
| 08.01.03 | Formulary | |
Nelarabine Atriance® |
| 08.02.04 | Formulary | |
Niraparib (Zejula®) |
| 08.02.04 | Formulary | |
Nivolumab Opdivo® |
| 08.02.03 | Formulary | |
Obinutuzumab Gazyvaro ® |
| 08.02.04 | Formulary | |
Osimertinib Tagrisso |
| 08.01.05 | Formulary | |
Paclitaxel - Albumin Bound Formulation Abraxane® |
| 05.03.05 | Restricted Use | |
Palivizumab Synagis® |
| 08.01.05 | Formulary | |
Pembrolizumab Keytruda® |
| 08.02.04 | Formulary | |
Pemrolizumab Keytruda® |
| 08.01.05 | Formulary | |
Pertuzumab Perjeta® |
| 08.02.04 | Formulary | |
Pomalidomide Imnovid® |
| 08.01.05 | Formulary | |
Regorafenib Stivarga® |
| 05.03.05 | Formulary | |
Ribavirin |
| 08.01.05 | Formulary | |
Ribociclib |
| 08.02.03 | Formulary | |
Rituximab MabThera®Truxima ® |
| 05.03.03.02 | Formulary | |
Sofosbuvir, Velpatasvir and Voxilaprevir Vosevi® |
| 08.01.05 | Formulary | |
Sorafenib Nexavar® |
| 08.01.05 | Formulary | |
Sunitinib Sutent® |
| 08.02.04 | Formulary | |
Talimogene laherparepvac Imlygic® |
| 08.02.04 | Formulary | |
Teriflunomide Aubagio® |
| 08.01.05 | Formulary | |
Tivozanib (Fotivda®) |
| 08.01.05 | Formulary | |
Trametinib Mekinist® |
| 08.01.05 | Formulary | |
Trastuzumab Herceptin® |
| 08.01.05 | Formulary | |
Trastuzumab emtansine Kadcyla® |
| 08.01.05 | Formulary | |
Trifluridine and Tipiracil Lonsurf ® |
| 08.01.05 | Formulary | |
Venetoclax Venclyxto ® |